Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kazia Therapeutics Limited - American Depositary Shares (NQ:KZIA)

0.9779 +0.0279 (+2.94%)
Streaming Delayed Price Updated: 2:24 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kazia Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Kazia Therapeutics (KZIA): Doubling Down on Clinical Development
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday, 52 stocks hit new 52-week lows. 
Via Benzinga
Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
Upgrades 
Via Benzinga
Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial
Via Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday. 
Via Benzinga
U.S. Stocks Turn Negative; Dow Drops Over 100 Points
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling more than 100 points on Monday. 
Via Benzinga
Stocks Finding Footing To Kick Off August
Stocks are trying to extend last month's impressive trading into August's first session. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Monday
  On Monday, 92 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session
Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022. 
Via Benzinga
U.S. Stocks Turn Higher; Crude Oil Tumbles
U.S. stocks turned higher midway through trading, after recording gains in the previous session. 
Via Benzinga
Why Stocks Are Trading Slightly Lower; U.S. Manufacturing PMI Slips
U.S. stocks traded slightly lower this morning, after recording gains in the previous session. 
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, trader! We're starting off Monday with a breakdown of the biggest pre-market stock movers traders will want to watch! 
Via InvestorPlace
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00... 
Via Benzinga
KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US
KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US Sydney, 20 July 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug... 
Via iCrowdNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
Kazia Therapeutics (KZIA) Stock Soars on FDA Designation
Kazia Therapeutics (KZIA) stock is taking off on Wednesday following an update from the FDA on its pediatric cancer treatment. 
Via InvestorPlace
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Kazia Shares Shoot Higher As FDA Grants Rare Pediatric Disease Designation To Brain Cancer Candidate
The United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia Therapeutics’ (NASDAQ: KZIA) lead drug Paxalisib for the treatment of atypical... 
Via Benzinga
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Kazia Therapeutics' Shares Gain Following FDA Orphan Drug Status For Childhood Brain Cancer Drug
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.